Previous close | 6.15 |
Open | 6.22 |
Bid | 6.20 x 200 |
Ask | 7.85 x 200 |
Day's range | 6.06 - 6.32 |
52-week range | 5.86 - 24.81 |
Volume | |
Avg. volume | 1,255,967 |
Market cap | 383.06M |
Beta (5Y monthly) | 1.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Best Medical Stocks to Buy Under $10. The healthcare sector spans medical stocks including biotechnology companies, health insurance […]